CLINICAL TRIALS PROFILE FOR RELISTOR
✉ Email this page to a colleague
All Clinical Trials for Relistor
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00672139 ↗ | Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness | Completed | Progenics Pharmaceuticals, Inc. | Phase 4 | 2008-07-01 | This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months. |
| NCT00672139 ↗ | Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness | Completed | Bausch Health Americas, Inc. | Phase 4 | 2008-07-01 | This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months. |
| NCT00672139 ↗ | Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness | Completed | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2008-07-01 | This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months. |
| NCT00672477 ↗ | Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness | Completed | Progenics Pharmaceuticals, Inc. | Phase 4 | 2008-06-01 | This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects. |
| NCT00672477 ↗ | Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness | Completed | Bausch Health Americas, Inc. | Phase 4 | 2008-06-01 | This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects. |
| NCT00672477 ↗ | Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness | Completed | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2008-06-01 | This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Relistor
Condition Name
Clinical Trial Locations for Relistor
Trials by Country
Clinical Trial Progress for Relistor
Clinical Trial Phase
Clinical Trial Sponsors for Relistor
Sponsor Name
